In last trading session, NovoCure Ltd (NASDAQ:NVCR) saw 1.14 million shares changing hands with its beta currently measuring 0.75. Company’s recent per share price level of $17.77 trading at $1.26 or 7.63% at ring of the bell on the day assigns it a market valuation of $1.98B. That closing price of NVCR’s stock is at a discount of -92.07% from its 52-week high price of $34.13 and is indicating a premium of 34.16% from its 52-week low price of $11.70. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.8 million shares which gives us an average trading volume of 865.29K if we extend that period to 3-months.
For NovoCure Ltd (NVCR), analysts’ consensus is at an average recommendation of Hold while assigning it a mean rating of 1.57. Splitting up the data highlights that, out of 5 analysts covering the stock, 1 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 3 suggested the stock as a Hold whereas 1 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.46 in the current quarter.
NovoCure Ltd (NASDAQ:NVCR) trade information
Upright in the green during last session for gaining 7.63%, in the last five days NVCR remained trading in the green while hitting it’s week-highest on Wednesday, 04/23/25 when the stock touched $17.77 price level, adding 0.22% to its value on the day. NovoCure Ltd’s shares saw a change of -40.37% in year-to-date performance and have moved 7.96% in past 5-day. NovoCure Ltd (NASDAQ:NVCR) showed a performance of -10.16% in past 30-days. Number of shares sold short was 5.42 million shares which calculate 5.87 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 30 to the stock, which implies a rise of 40.77% to its current value. Analysts have been projecting 30 as a low price target for the stock while placing it at a high target of 30. It follows that stock’s current price would drop -68.82% in reaching the projected high whereas dropping to the targeted low would mean a loss of -68.82% for stock’s current value.
NovoCure Ltd (NVCR) estimates and forecasts
This year revenue growth is estimated to rise 1.16% from the last financial year’s standing.
7 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 147M for the same. And 7 analysts are in estimates of company making revenue of 150.15M in the next quarter. Company posted 138.5M and 150.36M of sales in current and next quarters respectively a year earlier.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -83.87% during past 5 years. In 2025, company’s earnings growth rate is likely to be around -27.23% while estimates for its earnings growth in next 5 years are of 1.18%.
NovoCure Ltd (NASDAQ:NVCR)’s Major holders
Insiders are in possession of 9.70% of company’s total shares while institution are holding 86.43 percent of that, with stock having share float percentage of 95.72%. Investors also watch the number of corporate investors in a company very closely, which is 86.43% institutions for NovoCure Ltd that are currently holding shares of the company. FMR LLC is the top institutional holder at NVCR for having 16.14 million shares of worth $276.51 million. And as of 2024-06-30, it was holding 14.9875 of the company’s outstanding shares.
The second largest institutional holder is BLACKROCK INC., which was holding about 12.13 million shares on 2024-06-30. The number of shares represents firm’s hold over 11.265 of outstanding shares, having a total worth of $207.83 million.
On the other hand, SMALLCAP WORLD FUND INC and Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund are the top two Mutual Funds which own company’s shares. As of Mar 31, 2025 , the former fund manager was holding 8.34 shares of worth $148.21 million or 7.59% of the total outstanding shares. The later fund manager was in possession of 5.24 shares on Feb 28, 2025 , making its stake of worth around $93.05 million in the company or a holder of 4.76% of company’s stock.
